The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. PaxMedica's Revenue for the
three
months ended in Mar. 2024 was $0.00 Mil. PaxMedica's average Accounts Receivable for the
three
months ended in Mar. 2024 was $0.00 Mil.
PaxMedica Receivables Turnover Historical Data
The historical data trend for PaxMedica's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of PaxMedica's Receivables Turnover
For the Biotechnology subindustry, PaxMedica's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PaxMedica's Receivables Turnover Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, PaxMedica's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where PaxMedica's Receivables Turnover falls into.
PaxMedica Receivables Turnover Calculation
Receivables Turnover measures the number of times a company collects its average accounts receivable balance.
PaxMedica's Receivables Turnover for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
PaxMedica Receivables Turnover Related Terms
Thank you for viewing the detailed overview of PaxMedica's Receivables Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.
PaxMedica Inc is a clinical-stage biopharmaceutical company focusing on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms, ranging from neurodevelopmental disorders, including autism spectrum disorder (ASD), to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), a debilitating physical and cognitive disorder believed to be viral in origin and now with rising incidence globally due to the long term effects of SARS-CoV-2 (COVID-19). The company's product candidate under development is PAX-101, an intravenous formulation of suramin, which it is developing for multiple indications, including East African HAT, ASD, ME/CFS, and LCS.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PXMD has been successfully added to your 